Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
Analysts said that Argentina’s deal to postpone $2bn of debt owed to the Paris Club was a credit positive, though it was not enough to halt another recent fall in the sovereign’s bond prices as the medium-term likelihood of a default remains high. -
Since Friday last week the European Central Bank has stepped up asset purchases under its Pandemic Emergency Purchase Programme, giving secondary markets in rates products renewed vigour, said traders on Tuesday.
-
Zylox-Tonbridge Medical Technology, a China-based medical device maker, is looking to raise up to HK$2.56bn ($329.9m) from a Hong Kong IPO.
-
General Atlantic-owned Indian healthcare group Krishna Institute of Medical Sciences (Kims) has raised around Rp21.4bn ($288m) from a nearly four times subscribed IPO.
-
Biopharmaceutical company HutchMed (China) kicked off the roadshow for its HK$4.68bn ($602.7m) Hong Kong IPO on Friday, placing more than half of the shares in its third listing with cornerstone investors.
-
Shanghai Junshi Biosciences has raised HK$2.56bn ($330.5m) in equity capital from a placement of shares that drew a solid response from investors both during wall-crossing and bookbuilding.
